June 7, 2019

Regulations on the shortage of medicines in the Draft law converting the “Calabria” Law Decree

On May 3, 2019, Law Decree No. 35 of April 20, 2019 (the “Calabria Decree “) entered into force. The Calabria Decree includes significant provisions relating to the shortage of medicines.

To enable it legal effects, the Calabria Decree must be converted into a law within 60 days of entering into force. The draft law converting the Decree Calabria into a law (“Draft Law”) is currently being examined by Parliament. Specifically, on May 30, the Draft Law was approved by the Chamber of Deputies, with amendments to the text of the current Calabria Decree, and it is now to be examined by the Senate.

With regard to the shortage of medicines, the Draft Law provides for the following:

(i) in order to prevent or limit cases of shortage or of the unavailability of medicines on Italian territory, the Italian Medicines Agency (“AIFA”) issues a decision that temporarily bans exports of such medicines. AIFA is required to give prior notice of the adoption of this decision to the Ministry of Health.

This amendment was particularly appreciated by Federfarma (i.e., the Italian federation representing private pharmacies that are affiliated with the Italian National Health Service), which has seen this amendment as an important step forward in addressing the worrying phenomenon of the unavailability of certain categories of medicines on national territory, in order to safeguard public health.
However, it would be interesting to investigate whether this restriction on the export of specific medicines may conflict with the free movement of goods within the territory of the European Union, and how it may have an impact on the parallel import of medicines.

(ii) the marketing authorization holder shall notify AIFA of the temporary or permanent interruption of the marketing of any medicinal product in Italian territory not less than four months in advance of the date of interruption, rather than two months, as provided for in the current version of Legislative Decree No. 219 of April 24, 2006 (Drugs Code).
Any failure to comply with this obligation is subject to an administrative penalty, the amount of which ranges from EUR 3,000 to 18,000.

(iii) To increase monitoring on national territory that aims to prevent any situations in which there is a shortage of medicines, the Draft Law introduces to AIFA the positions of administrative director and technical-scientific director.

As indicated above, these provisions are currently being assessed by the Italian Parliament and they are still subject to further amendments until the Draft Law is finally approved (by July 3, 2019).

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

Close
March 20, 2023
Today, Regulation (EU) 2023/607 extending the transitional provisions for the placing on the market and putting into service of certain medical devices and in vitro diagnostic medical device...
January 31, 2023
Clinical trials: Ministry of Health signed off on decrees that (i) reorganize ethics committees and coordinate their activities, (ii) determine the single tariff for the authorization proced...
December 19, 2022
On 13 December 2022, EMA, European Commission and HMA jointly adopted a recommendation paper on the introduction of decentralised elements in the conduct of Clinical Trials in the EU/EEA
September 21, 2022
Payback for medical devices: Decree quantifying the exceeding of the expenditure ceiling for medical devices at national and regional level for the years 2015, 2016, 2017 and 2018 published ...
September 1, 2022
The 2021 annual law for market and competition addressing, as to the healthcare sector, reimbursement of drugs, intermediate distribution, patent linkage and institutional accreditation of p...
Search by...
Search
Follow us on
Follow us on